Acumen Pharmaceuticals (ABOS) News Today → 41 banks launch ‘crypto dollar’ (From Stansberry Research) (Ad) Free ABOS Stock Alerts $3.84 +0.19 (+5.21%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 2:43 AM | americanbankingnews.comHC Wainwright Comments on Acumen Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ABOS)May 17 at 8:25 AM | marketbeat.comHC Wainwright Weighs in on Acumen Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ABOS)Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - HC Wainwright boosted their Q2 2024 earnings per share (EPS) estimates for Acumen Pharmaceuticals in a report released on Wednesday, May 15th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.25) per share forMay 17 at 2:00 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Acumen Pharmaceuticals (NASDAQ:ABOS)May 16, 2024 | markets.businessinsider.comBuy Rating Justified: Acumen Pharmaceuticals’ Promising Position in Alzheimer’s Treatment MarketMay 16, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)May 15, 2024 | marketbeat.comAcumen Pharmaceuticals (NASDAQ:ABOS) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Acumen Pharmaceuticals in a research note on Wednesday.May 15, 2024 | finance.yahoo.comQ1 2024 Acumen Pharmaceuticals Inc Earnings CallMay 15, 2024 | finance.yahoo.comAcumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | americanbankingnews.comShort Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Declines By 11.7%May 14, 2024 | investorplace.comABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | msn.comAcumen Pharmaceuticals GAAP EPS of -$0.25May 14, 2024 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Decrease in Short InterestAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large drop in short interest in April. As of April 30th, there was short interest totalling 926,900 shares, a drop of 11.7% from the April 15th total of 1,050,000 shares. Based on an average daily volume of 320,100 shares, the short-interest ratio is presently 2.9 days. Currently, 2.1% of the shares of the stock are short sold.May 14, 2024 | globenewswire.comAcumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business HighlightsMay 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Acumen Pharmaceuticals Based on Strategic Alzheimer’s Treatment Approach and Promising Clinical ProspectsMay 13, 2024 | globenewswire.comAcumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 12, 2024 | americanbankingnews.comAcumen Pharmaceuticals (ABOS) to Release Quarterly Earnings on TuesdayMay 8, 2024 | globenewswire.comAcumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare ConferenceMay 8, 2024 | finance.yahoo.comAcumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s DiseaseMay 8, 2024 | globenewswire.comAcumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's DiseaseMay 7, 2024 | globenewswire.comAcumen Pharmaceuticals to Report First Quarter Results on May 14, 2024April 18, 2024 | markets.businessinsider.comThese 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say AnalystsApril 17, 2024 | msn.comAcumen Pharmaceuticals (ABOS) Price Target Increased by 6.67% to 13.06April 16, 2024 | globenewswire.comAcumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual MeetingApril 4, 2024 | finance.yahoo.comAcumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s TreatmentApril 4, 2024 | markets.businessinsider.comAcumen Pharma Partners Lonza To Advance Sabirnetug For Alzheimer's Disease TreatmentApril 4, 2024 | finance.yahoo.comAcumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s DiseaseApril 4, 2024 | globenewswire.comAcumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's DiseaseApril 4, 2024 | msn.comSames Auto Group partners with Driscoll Children’s HospitalMarch 29, 2024 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) to Post Q2 2024 Earnings of ($0.26) Per Share, HC Wainwright ForecastsAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - HC Wainwright issued their Q2 2024 earnings per share (EPS) estimates for shares of Acumen Pharmaceuticals in a research note issued on Wednesday, March 27th. HC Wainwright analyst A. Fein anticipates that the company will post earnings oMarch 28, 2024 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Forecasted to Post Q1 2024 Earnings of ($0.26) Per ShareAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Acumen Pharmaceuticals in a report issued on Wednesday, March 27th. HC Wainwright analyst A. Fein forecasts that the company will post earninMarch 27, 2024 | msn.comAcumen Pharmaceuticals files for $200M mixed shelf offeringMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acumen Pharmaceuticals on Promising Alzheimer’s Drug Trial OutcomesMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Alzheimer’s Treatment Development and Attractive ValuationMarch 27, 2024 | finance.yahoo.comQ4 2023 Acumen Pharmaceuticals Inc Earnings CallMarch 27, 2024 | finance.yahoo.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | globenewswire.comAcumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business HighlightsMarch 20, 2024 | marketbeat.comAcumen Pharmaceuticals (ABOS) Scheduled to Post Quarterly Earnings on TuesdayAcumen Pharmaceuticals (NASDAQ:ABOS) will be releasing earnings before the market opens on Tuesday, March 26, Zacks reports.March 19, 2024 | globenewswire.comAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024March 12, 2024 | globenewswire.comAcumen Pharmaceuticals to Participate in the Stifel 2024 CNS DaysMarch 8, 2024 | finance.yahoo.comAcumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual MeetingMarch 7, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Takes $2.68 Million Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)Schonfeld Strategic Advisors LLC acquired a new position in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 645,112 shares of the companFebruary 24, 2024 | finance.yahoo.comInstitutional investors own a significant stake of 42% in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)February 21, 2024 | finance.yahoo.comAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual MeetingFebruary 21, 2024 | globenewswire.comAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual MeetingFebruary 17, 2024 | finance.yahoo.comABOS Mar 2024 2.500 putFebruary 7, 2024 | finance.yahoo.comBuy Alert: 3 Healthcare Stocks Sitting in the Sweet SpotFebruary 1, 2024 | finance.yahoo.com3 Healthcare Stocks to Buy as the Sector Benefits from the Aging BoomFebruary 1, 2024 | finance.yahoo.comAcumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development OfficerJanuary 19, 2024 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells $10,567.09 in StockAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) COO Russell Barton sold 2,833 shares of Acumen Pharmaceuticals stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $3.73, for a total value of $10,567.09. Following the transaction, the chief operating officer now owns 96,867 shares of the company's stock, valued at $361,313.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 8, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Acumen Pharmaceuticals (ABOS) Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address 41 banks launch ‘crypto dollar’ (Ad)Everyone knows the US financial system is in the middle of a radical change... The White House wants an all-digital dollar. Plus at least 41 major banks (see if your bank is one of them right here). Here's how you capitalize (including #1 crypto to play it). ABOS Media Mentions By Week ABOS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABOS News Sentiment▼0.470.42▲Average Medical News Sentiment ABOS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABOS Articles This Week▼192▲ABOS Articles Average Week Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CMPX News Today ZURA News Today AGEN News Today OVID News Today IPHA News Today OPT News Today INMB News Today CHRS News Today IPSC News Today KOD News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABOS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDems have chosen Biden replacement?Paradigm PressDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
